CHICAGO, May 9, 2024 /PRNewswire/ — According to Arizton’s latest research report, the Australia data center market is growing at a CAGR of 3.22% during 2023-2029.

To Know More, Click: https://www.arizton.com/market-reports/australia-data-center-market-investment-analysis
Australia Data Center Market Report Scope
Report Attributes
Details
Market Size (Investment)
USD 7.71 Billion (2029)
Market Size (Area)
1,460.0 thousand sq. Feet (2029)
Market Size (Power Capacity)
303.0 MW (2029)
CAGR Investment (2023-2029)
3.22 %
Colocation Market Size (Revenue)
USD 2.05 Billion (2029)
Historic Year
2020-2022
Base Year
2023
Forecast Year
2024-2029
The data center market in Australia has been witnessing significant growth in investments over the past few years. It is expected to grow at an absolute growth rate of around 20% between 2023-2029. Australia is among the top destinations for data center investments in the APAC region.
Sydney, Melbourne, and Perth are the primary data center hubs hosting most data centers in the country. Canberra, Brisbane, Darwin, and other cities are among the emerging locations in Australia with abundant land availability for data center development.
Investment Opportunities
In November 2023, OVHcloud announced the launch of its upcoming SYD3 Sydney data center facility, which is expected to be operational in 2024.In November of 2023, Rest Super invested about $656 million in a data center in Brisbane, which Quinbrook Infrastructure Partners are developing.In November 2023, NEXTDC announced the development of the D1 data center facility in Darwin; the facility is expected to go operational by Q2 2024.AirTrunk announced the expansion of its SYD2 data center campus in Sydney; once fully built, the facility will account for an additional power capacity of around 30 MW, making it an aggregate capacity of around 120 MW. This second phase is expected to be completed in 2024. AirTrunk’s upcoming SYD3 Sydney facility calls for an aggregate investment of about $670 million.In an August 2023 news article, Macquarie Data Centres revealed its plan to expand its upcoming IC3 Super West facility in Sydney regarding power capacity. As per January 2024 news article, Macquarie Data Centres has received approval to build/grow the IC3 Super West, its third facility in Sydney.In August 2023, STACK Infrastructure announced the MEL01 A data center launch in Melbourne, located at 399 Palmers Road. The entire campus will have a power capacity of around 72 MW, divided equally between buildings A and B. As of early 2024, Building B is still a work in progress. Furthermore, the company plans new facilities in Canberra, Hume, and Perth.Rising Procurement of Renewable Energy in Australia Boosting the Market Opportunities
In 2022, according to IRENA, solar energy accounted for around 61% of Australia’s overall renewable energy capacity, followed by wind, hydro, and bioenergy (in decreasing order), from which renewable power is extracted for all the sustainable energy needs of the country. Australia aims to achieve its target of zero carbon emissions by 2050. The country announced plans to reach almost 43% less emission than in 2005.
According to the Australia National Electricity Market (NEM), the renewable energy share in the country is expected to reach around 41% by 2030. By 2025, Australia aims to achieve 100% instantaneous renewable energy for its main grid, starting with a half-hour period and gradually increasing to cover hours and days. This transition will be facilitated by an increase in wind, solar, and energy storage solutions to meet the country’s new target of 82% renewables by 2030. The retirement of coal-based power generation facilities in the coming years will contribute to this goal.
Microsoft in Australia Recent Development During 2022-2024:
In October 2023, Microsoft, a hyperscale tech giant, decided to expand its footprint in Australia by investing over $3 billion to increase and expand its computing capacity in the country by over 250% in the next two years. It is expected to go live by late 2025.In July 2023, Microsoft announced the completion of the construction of Building 1 of the Station Road data center; Building 2 is still a work in progress. This is expected to be completed by late 2024.Why Should You Buy This Research? 
Market size is available in terms of investment, area, power capacity, and Australia colocation market revenue.An assessment of the data center investment in Australia by colocation, hyperscale, and enterprise operators.Investments in the area (square feet) and power capacity (MW) across cities in the country.A detailed study of the existing Australia data center market landscape, an in-depth market analysis, and insightful predictions about market size during the forecast period.Snapshot of existing and upcoming third-party data center facilities in AustraliaFacilities Covered (Existing): 135Facilities Identified (Upcoming): 23Coverage: 20 LocationsExisting vs. Upcoming (Area)Existing vs. Upcoming (IT Load Capacity)Data Center Colocation Market in the AustraliaColocation Market Revenue & Forecast (2023-2029)Retail Colocation Revenue (2023-2029)Retail Colocation PricingThe Australia data center market investments are classified into IT, power, cooling, and general construction services with sizing and forecast.A comprehensive analysis of the latest trends, growth rate, potential opportunities, growth restraints, and prospects for the industry.Business overview and product offerings of prominent IT infrastructure providers, construction contractors, support infrastructure providers, and investors operating in the market.A transparent research methodology and the analysis of the demand and supply aspects of the market.Market Segmentation
IT InfrastructureServersStorage SystemsNetwork InfrastructureElectrical InfrastructureUPS SystemsGeneratorsSwitches & SwitchgearsPDUsOther Electrical InfrastructureMechanical InfrastructureCooling SystemsRack CabinetsOther Mechanical InfrastructureCooling SystemsCRAC and CRAHChillersCooling Towers, Condensers and Dry CoolersEconomizers and Evaporative CoolersOther Cooling UnitsGeneral ConstructionCore & Shell DevelopmentInstallation & commissioning ServicesBuilding & Engineering DesignFire Detection & Suppression SystemsPhysical SecurityData Center Infrastructure Management (DCIM)Tier StandardTier I & Tier IITier IIITier IVGeographySydneyMelbournePerthOther CitiesVendor Landscape
IT Infrastructure Providers: Arista Networks, Atos, Broadcom, Cisco Systems, Dell Technologies, Extreme Networks, Hewlett Packard Enterprise, Hitachi Vintara, IBM, Juniper Networks, Lenovo, Oracle, Pure Storage, Quanta Cloud Technology, and Super Micro Computer.Data Center Construction Contractors & Sub-Contractors: AECOM, A W Edwards, Aurecon, Benmax, BGIS, Dem, FDC Construction & Fitout, FKG Group, Greenbox Architecture, HDR (Hurley Palmer Flatt), Hutchinson Builders, Icon, ISG, John Holland, Kapitol Group, Linesight, Manteena Group, Nilsen, Paramount Airconditioning, Parratech, SCEE Group, Stowe Australia, & Taylor Group Construction.Support Infrastructure Providers: ABB, Airedale, Alfa Laval, Canovate, Caterpillar, Condair, Cummins, Delta Electronics, Eaton, Everett Smith & Co, Green Revolution Cooling, HITEC Power Protection, Kohler, Legrand, Mitsubishi Electric, Piller Power Systems, Rittal, Rolls Royce, Schneider Electric, STULZ, Thycon, & Vertiv.Data Center Investors: 5G Networks, AirTrunk, Amazon Web Services, CDC Data Centres, DC Two, DCI Data Centers, Digital Realty, Equinix, Edge Centres, Fujitsu, Global Switch, Leading Edge Data Centres, Keppel Data Centres, Macquarie Data Centres, Microsoft, NEXTDC, & STACK Infrastructure.New Entrants: GreenSquareDC, Stockland, Supernode, Trifalga, & Vantage Data Centers.Key Questions Answered in the Report:
Q: How big is the Australia data center market?
Q: How much MW of power capacity will be added across Australia from 2024 to 2029?
Q: What is the growth rate of the Australia data center market?
Q: What factors are driving the Australia data center market?
Q: Which cities are included in the Australia data center market report?
Get the Detailed TOC @ https://www.arizton.com/market-reports/australia-data-center-market-investment-analysis
Check Out Some of the Top Selling Research Reports:    
Singapore Data Center Market – Investment Analysis & Growth Opportunities 2024-2029
South Korea Data Center Market – Investment Analysis & Growth Opportunities 2024-2029
Indonesia Data Center Market – Investment Analysis & Growth Opportunities 2024-2029
Taiwan Data Center Market – Investment Analysis & Growth Opportunities 2024-2029
Why Arizton?                 
100% Customer Satisfaction                 
24×7 availability – we are always there when you need us                 
200+ Fortune 500 Companies trust Arizton’s report                 
80% of our reports are exclusive and first in the industry                 
100% more data and analysis                 
1500+ reports published till date                  
About Us:                                                      
Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                    
We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                     
Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                           
Contact Us                                                   Call: +1-312-235-2040                                                            +1 302 469 0707                                                 Mail: [email protected]                                                   Contact Us: https://www.arizton.com/contact-us                                                   Blog: https://www.arizton.com/blog                                                   Website: https://www.arizton.com/
Photo: https://mma.prnewswire.com/media/2408813/Australia_Data_Center_Market.jpgLogo: https://mma.prnewswire.com/media/818553/Arizton_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/the-australia-data-center-market-size-will-witness-investments-of-7-71-billion-by-2029—get-insights-on-135-existing-data-centers-and-23-upcoming-facilities-across-australia—arizton-302141457.html

Report recognises Invoca’s innovative platform for delivering “game-changing AI capabilities to revenue teams.”
SANTA BARBARA, Calif., May 9, 2024 /PRNewswire/ — Invoca today announced that Forrester Research has named Invoca as a Leader in The Forrester Wave™: Real-Time Revenue Execution Platforms, Q2 2024 report. Forrester evaluated the most significant revenue execution platform vendors based on three main categories — current offering, strategy, and market presence — along with interviews with customers. Invoca is the top-ranked vendor in both the current offering and strategy categories and among the top-ranked in market presence. Invoca also received the highest possible score in 19 of the 31 evaluation criteria, including AI differentiators, AI: large language model utilisation, Marketing: performance optimisation, In-call guidance: pre-call insights, System configuration: privacy, and Interaction capture: integrations.

The report states, “[Invoca’s] success starts with a vision focused on enabling revenue teams to drive growth by delivering the most complete platform for optimising the entire buying experience. Invoca has a track record of innovation that continues to raise the bar on what is possible to fulfil its vision.”
Revenue Execution Platforms Unify the Buying Journey to Drive Revenue Growth
Invoca’s revenue execution platform enables revenue teams to connect customer buying journey data across the marketing team that engages customers and the sales teams that close the deals. By using a comprehensive revenue execution platform, revenue teams can finally connect their marketing investments directly to revenue, improve digital engagement, and drive higher-quality leads.
Invoca also enables sales teams in the contact centre or at distributed business locations to access information from the customer’s digital journey from a centralised source, enabling them to provide the best call experience possible and close more sales opportunities.
Revenue Execution Platforms Needed to Power Today’s Buyer Journey
“B2C revenue teams across marketing and sales are feeling more pressure to directly connect revenue to their investments. But a lack of alignment and poor visibility of the full buying journey makes that nearly impossible,” said Peter Isaacson, Chief Marketing Officer at Invoca. “I believe Invoca was named a revenue execution Leader because we help marketing and sales teams manage the complete buyer journey from the first click to the final sale, so they can drive revenue growth.”
By using Invoca’s comprehensive revenue execution platform, revenue teams can connect their paid media investments directly to revenue, improve digital engagement and deliver the best buyer experiences to drive more sales. The Forrester report states that “reference customers rave about the versatility of the platform and its collaboration with customers around enhancements.”
Windstream, an Invoca customer, embodies this approach to revenue execution by tightly aligning the marketing and sales teams so they can work together to increase revenue.
“‍We’re a better marketing organisation because we have a strong partnership with sales,” said Aaron Pierce, VP of Marketing at Windstream. “Our teams have realised that we make each other better — I think that’s the biggest win. And now, when we have a problem, we can put all the smartest people together in the room to tackle it.”
“The Invoca platform has allowed us to unlock a ‘full-funnel’ view of our marketing performance that incorporates both online and offline,” said Lorenzo Clark, VP of Digital Sales at Windstream. “Now, we can get a read on lead quality because we can see what’s happening on sales calls and also track sales performance on a lead-by-lead basis.”
The Forrester Wave™The Forrester Wave™ is Forrester’s evaluation of top products in a technology market. The report assesses the core capabilities and strategies of these products based on an executive strategy briefing and/or product demo session, criteria questionnaire, and customer reference calls/surveys.
The Forrester Wave™: Real-Time Revenue Execution Platforms, Q2 2024 report is available for download here.
Additional Resources:
Learn more about Revenue Execution Platforms: https://www.invoca.com/uk/product/revenue-execution-platformHow real-time revenue execution platforms drive business growth: https://www.invoca.com/uk/blog/revenue-execution-platformThe 5 Revenue Execution Platform Uses You Need to Know About: https://www.invoca.com/uk/blog/revenue-execution-platform-usesAbout InvocaInvoca is the leading revenue execution platform to connect marketing and sales teams to enable them to track and optimise the buying journey and drive more revenue. By using a comprehensive revenue execution platform with deep integrations with leading technology platforms, revenue teams can better connect their paid media investments directly to revenue, improve digital engagement, and deliver the best buyer experiences to drive more sales. With Invoca, top consumer brands, including AutoNation, DIRECTV, Mayo Clinic, Mutual of Omaha, and Verizon, experience unbelievable results powered by undeniable data. Invoca has raised $184M from leading venture capitalists, including Upfront Ventures, Accel, Silver Lake Waterman, H.I.G. Growth Partners, and Salesforce Ventures. For more information, visit www.invoca.com.
Logo – https://mma.prnewswire.com/media/815871/Invoca_Master_Logo_2x_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/invoca-named-a-leader-in-real-time-revenue-execution-platforms-report-302141481.html

FN Media Group News Commentary
PALM BEACH, Fla., May 9, 2024 /PRNewswire/ — The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society predicts that 64,050 Americans will be diagnosed with pancreatic cancer. It is estimated that 50,550 people will die from pancreatic cancer (26,620 men and 23,930 women). Pancreatic cancer is an aggressive form of cancer, and it is often not detected until it is in an advanced stage. Additionally, the treatment options for pancreatic cancer are limited, and the survival rate is low. These factors are contributing to the rise in pancreatic cancer cases, which in turn is driving the growth of the pancreatic cancer market.  A recent report from Research Nester projected that the global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 36 billion by the end of 2036, up from a revenue of ~USD 6 billion in the year 2023. The report said: “Advancements in diagnosis and treatment options for pancreatic cancer are also driving the growth of the market. As researchers gain a better understanding of the different types of pancreatic cancer, they are developing more targeted treatments that are more likely to be effective with fewer side effects. Additionally, new treatment options, such as immunotherapy and targeted therapies, are improving patient outcomes and extending survival rates.”  Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), Zai Lab Limited (NASDAQ: ZLAB), Notable Labs, Ltd. (NASDAQ: NTBL), Cardiff Oncology, Inc. (NASDAQ: CRDF), Johnson & Johnson (NYSE: JNJ).

Research Nester concluded: “The pancreatic cancer market in North America is garner the largest revenue by the end of 2036 due to several demographic changes, including an aging population and increased incidence of obesity and diabetes. In the US, there are 37.3 million diabetics (11.3[R3] % of the population); 28.7 million are diagnosed with diabetes, including 28.5 million adults. As the population ages, there will be a higher prevalence of chronic diseases such as diabetes and obesity, which are risk factors for pancreatic cancer. Additionally, the aging population will lead to an increase in the number of people with pre-existing conditions that can increase the risk of developing pancreatic cancer. Obesity and diabetes are known risk factors for pancreatic cancer, and as these conditions become more prevalent, the number of cases of pancreatic cancer is expected to increase.”
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer 
US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study  Study of modified OLFIRINOX/pelareorep/atezolizumab (Tecentriq ®) combination expands existing pancreatic cancer program  First patient expected to be enrolled in Q2 2024 Oncolytics Biotech ® Inc., a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq ® ) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer. The chemotherapy regimens of mFOLFIRINOX or gemcitabine + nab-paclitaxel are the two most common standards of care for pancreatic cancer.  Oncolytics has already reported data with the combination of gemcitabine and nab-paclitaxel ( link to the PR , link to the poster ) that surpassed historical outcomes. Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep’s potential in addressing pancreatic cancer.
“Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC. We appreciate the opportunity to collaborate with PanCAN, Roche, and AIO on this cohort, which is expected to initiate enrollment in the second quarter,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. “We believe that working with PanCAN will help to further enrich Oncolytics’ clinical relationships with the pancreatic cancer community. We are also grateful for PanCAN’s Therapeutic Accelerator Award, which is enabling the evaluation of this combination therapy.”
“The Therapeutic Accelerator Award program has been an important part of PanCAN’s approach to advancing innovative treatments for pancreatic cancer. We incorporated input from leading scientists and clinicians in the field of pancreatic cancer to select Oncolytics as a recipient of this award,” said Anna Berkenblit , MD, MMSc, Chief Scientific and Medical Officer at PanCAN. “Increasing patient access to clinical trials is vital to developing improved treatment options, so we are pleased that Oncolytics has received regulatory clearance for the pelareorep/mFOLFIRINOX combination and is poised to enroll the first patient in this cohort. We hope that the results from this study lead to improved outcomes for patients with pancreatic cancer.”
Dirk Arnold , M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial, commented, “Oncolytics has taken a very strategic approach to the development of pelareorep in pancreatic cancer by focusing its clinical studies on combinations with the most widely used treatment regimens. My experience to date with the GOBLET study, including the positive metastatic PDAC and encouraging anal cancer data reported last year, makes me enthusiastic to initiate enrollment in the mFOLFIRINOX cohort.”
“We previously reported very encouraging results in pancreatic cancer patients for the combination of pelareorep, gemcitabine/nab-paclitaxel, and atezolizumab, and we plan to begin a registration-enabling study of this regimen later this year. The new pelareorep/mFOLFIRINOX cohort offers the opportunity to expand pelareorep’s role in pancreatic cancer. If the mFOLFIRINOX combination shows a compelling efficacy signal, this therapeutic approach could also be advanced to a registration-enabling study, providing two opportunities for pelareorep-based treatment to benefit pancreatic cancer patients,” said Thomas Heineman , M.D., Ph.D., Chief Medical Officer at Oncolytics. “In addition, translational research studies planned for this cohort will help to further elucidate pelareorep’s mechanism of action, including its ability to shape the tumor microenvironment (TME). Notably, we will evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs) in the blood, an effect that was observed in earlier pancreatic cancer studies. We look forward to initiating enrollment into the mFOLFIRINOX/pelareorep study cohort in the second quarter of this year.” CONTINUED… Read these full press releases and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/  
Other recent developments in the biotech industry of note for cancer events include:
Zai Lab Limited (NASDAQ: ZLAB) recently announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates. “Our first quarter results demonstrate strong commercial execution and pipeline progress across our potential first- and best-in-class product portfolio,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “The launch of VYVGART is off to an impressive start with $13.2 million of sales in the first quarter. Looking ahead, we expect to accelerate commercial performance for the remainder of the year and are preparing for three new potential launches in 2024. We are also excited by the progress of our late-stage pipeline and we are on track to achieve the objectives outlined in our five-year strategic plan, including significant revenue growth and profitability by the end of 2025.”
“Our net revenues grew 39% y-o-y or 43% y-o-y at CER in the first quarter, driven by strong execution with the launch of VYVGART and uptake of our existing portfolio,” said Josh Smiley, President and Chief Operating Officer of Zai Lab. “With VYVGART’s launch in gMG at the end of last year, and multiple new products and indications expected to launch over the near-term, we are now entering a period of robust growth for Zai Lab. Our significant growth, coupled with our focus on driving efficiencies and productivity across the organization, will drive the evolution of Zai Lab into a profitable, high growth business by the end of 2025. Furthermore, we will continue to focus on expanding our global portfolio through our internal discovery activities and strategic business development,” Mr. Smiley concluded.
Notable Labs, Ltd. (NASDAQ: NTBL), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), recently reported financial results for the year ended December 31, 2023 and provided a business update.
“The last year has been a time of great accomplishment for Notable. We built a strong clinical validation dataset, starting with a poster presented at the American Association for Cancer Research (AACR 2023); became a publicly listed company, following the closing of a reverse merger in October 2023; and reported successful PPMP clinical data from the Phase 2 fosciclopirox study that showcased the ability of our platform to accurately predict patient outcomes for specific therapeutics,” said Thomas Bock, M.D., Chief Executive Officer of Notable. “The performance of our platform in accurately predicting the outcome of the fosciclopirox study has enabled us to enhance the clinical trial plan for our lead product candidate, volasertib, in development for patients with relapsed/refractory acute myeloid leukemia (r/r AML). In our upcoming Phase 2 trial, we will be utilizing the platform to enrich the study’s enrollment with patients predicted to respond to volasertib, which we believe will result in more rapid enrollment, shorter time to efficacy data and, ultimately, increased probability of success.”
Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced financial results for the first quarter ended March 31, 2024, and provided a business update.
“During the start of 2024, we presented several important new data sets supporting our first-line RAS-mutated mCRC strategy and the broader opportunity for onvansertib,” said Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology. “The data from the ONSEMBLE trial replicated, in a second independent and randomized dataset, the bev naïve signal from our earlier Phase 1b/2 KRAS-mutated mCRC trial. And the Phase 1b data published in the peer-reviewed journal Clinical Cancer Research, and the additional data we presented in one of our five posters at AACR, further substantiated our lead program in RAS-mutated mCRC. The additional AACR posters also point toward new indications for onvansertib in RAS wild-type mCRC, small cell lung cancer and ovarian cancer. Looking ahead, we believe that our upcoming data readout from our first-line trial in RAS-mutated mCRC has the potential to serve as a key value inflection point for our company and revolutionize the treatment of RAS-mutated mCRC, an area with no new treatments approved in over two decades.”
Johnson & Johnson (NYSE: JNJ) recently announced that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.
FDA approval is based on positive results from the Phase 3 CARTITUDE-4 study, which demonstrated that the earlier use of CARVYKTI® reduced the risk of disease progression or death by 59 percent compared to standard therapies—pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd)—in adults with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy. The study, which was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and published in The New England Journal of Medicine, also included and reported key secondary results such as overall response (OR) and overall survival (OS).
About FN Media Group:
At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies. #pressreleases #tickertagpressreleases
Follow us on Facebook to receive emerging news updates: https://www.facebook.com/financialnewsmedia
Follow us on Twitter for real time Breaking News: https://twitter.com/FNMgroup
Follow and us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty nine hundred dollars for news coverage of the current press releases issued by Oncolytics Biotech® Inc.  by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: [email protected] – +1(561)325-8757 
 
 

View original content:https://www.prnewswire.co.uk/news-releases/fight-against-pancreatic-cancer-ramps-up-as-market-size-revenues-expected-to-exceed-36-billion-by-2036-302141437.html